264 related articles for article (PubMed ID: 2821890)
1. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
Ellis MN; Keller PM; Fyfe JA; Martin JL; Rooney JF; Straus SE; Lehrman SN; Barry DW
Antimicrob Agents Chemother; 1987 Jul; 31(7):1117-25. PubMed ID: 2821890
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir.
McLaren C; Chen MS; Ghazzouli I; Saral R; Burns WH
Antimicrob Agents Chemother; 1985 Dec; 28(6):740-4. PubMed ID: 3002245
[TBL] [Abstract][Full Text] [Related]
3. An acyclovir-resistant strain of herpes simplex virus type 2 which is highly virulent for mice.
Sakuma S; Yamamoto M; Kumano Y; Mori R
Arch Virol; 1988; 101(3-4):169-82. PubMed ID: 2845890
[TBL] [Abstract][Full Text] [Related]
4. Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Fyfe JA; McKee SA; Keller PM
Mol Pharmacol; 1983 Sep; 24(2):316-23. PubMed ID: 6310366
[TBL] [Abstract][Full Text] [Related]
5. Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model.
Coen DM; Irmiere AF; Jacobson JG; Kerns KM
Virology; 1989 Feb; 168(2):221-31. PubMed ID: 2536980
[TBL] [Abstract][Full Text] [Related]
6. Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir.
Oliver NM; Collins P; Van der Meer J; Van't Wout JW
Antimicrob Agents Chemother; 1989 May; 33(5):635-40. PubMed ID: 2546486
[TBL] [Abstract][Full Text] [Related]
7. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.
Darby G; Field HJ; Salisbury SA
Nature; 1981 Jan; 289(5793):81-3. PubMed ID: 6256650
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.
Larder BA; Darby G
Virology; 1985 Oct; 146(2):262-71. PubMed ID: 2996220
[TBL] [Abstract][Full Text] [Related]
9. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.
Collins P; Ellis MN
J Med Virol; 1993; Suppl 1():58-66. PubMed ID: 8245894
[TBL] [Abstract][Full Text] [Related]
11. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing.
Rubsam LZ; Davidson BL; Shewach DS
Cancer Res; 1998 Sep; 58(17):3873-82. PubMed ID: 9731497
[TBL] [Abstract][Full Text] [Related]
12. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir.
Field HJ; Lay E
Antiviral Res; 1984 Apr; 4(1-2):43-52. PubMed ID: 6331304
[TBL] [Abstract][Full Text] [Related]
13. Alterations in substrate specificity and physicochemical properties of deoxythymidine kinase of a drug-resistant herpes simplex virus type 1 mutant.
Veerisetty V; Gentry GA
J Virol; 1983 Jun; 46(3):901-8. PubMed ID: 6304349
[TBL] [Abstract][Full Text] [Related]
14. Deoxythymidine kinase induced in the HELA TK- cells by herpes simplex virus type I and type II. Substrate specificity and kinetic behavior.
Cheng YC
Biochim Biophys Acta; 1976 Dec; 452(2):370-81. PubMed ID: 188465
[TBL] [Abstract][Full Text] [Related]
15. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
Saijo M; Suzutani T; Yoshida I
Tohoku J Exp Med; 1992 May; 167(1):57-68. PubMed ID: 1333651
[TBL] [Abstract][Full Text] [Related]
16. Thymidine kinase with altered substrate specificity of acyclovir resistant varicella-zoster virus.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1986 Mar; 29(1):7-10. PubMed ID: 3022711
[TBL] [Abstract][Full Text] [Related]
17. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.
Roberts GB; Fyfe JA; Gaillard RK; Short SA
J Virol; 1991 Dec; 65(12):6407-13. PubMed ID: 1658351
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity.
Tanaka S; Toh Y; Mori R
Arch Virol; 1993; 131(1-2):61-73. PubMed ID: 8392322
[TBL] [Abstract][Full Text] [Related]
19. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1.
Bae PK; Kim JH; Kim HS; Chung IK; Paik SG; Lee CK
Antiviral Res; 2006 Jul; 70(3):93-104. PubMed ID: 16546268
[TBL] [Abstract][Full Text] [Related]
20. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency.
Schinazi RF; del Bene V; Scott RT; Dudley-Thorpe JB
J Antimicrob Chemother; 1986 Oct; 18 Suppl B():127-34. PubMed ID: 3025153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
